Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Sarepta Therapeutics Inc (SRPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sarepta's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
115.62 -0.93    -0.80%
21:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
115.62
-0.00
-0.00%
21:29:18 - Real-time Data
  • Volume: 624,242
  • Bid/Ask: 114.00 / 129.87
  • Day's Range: 114.38 - 117.74
Type:  Equity
Market:  United States
Sarepta 115.62 -0.93 -0.80%

NASDAQ:SRPT Financials

 
This summary provides an overview of the most significant critical numbers from each of the Sarepta financial reports, including theSarepta Therapeutics Inc income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the NASDAQ:SRPT financials over time via breakdowns of their annual reports.

Sarepta Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 396.78 million compared to USD 258.43 million a year ago. Net income was USD 45.66 million compared to net loss of USD 109.24 million a year ago. Basic earnings per share from continuing operations was USD 0.49 compared to basic loss per share from continuing operations of USD 1.24 a year ago. Diluted earnings per share from continuing operations was USD 0.47 compared to diluted loss per share from continuing operations of USD 1.24 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SRPT Income Statement & Profits

Gross margin TTM 17.34%
Operating margin TTM -21.54%
Net Profit margin TTM -43.11%
Return on Investment TTM -10.82%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 396.78 331.82 261.24 253.5
Gross Profit 157.09 100.49 -14.78 -27.2
Operating Income 24.62 -20.84 -133.52 -138.09
Net Income 45.66 -40.94 -23.94 -516.76

SRPT Balance Sheet

Quick Ratio MRQ 3.22
Current Ratio MRQ 3.95
LT Debt to Equity MRQ 131.79%
Total Debt to Equity MRQ 162.54%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 3264.58 3109.71 3125.89 3059.79
Total Liabilities 2405.24 2345.35 2384.48 2347.04
Total Equity 859.34 764.36 741.41 712.75

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -5.36
Revenue/Share TTM 13.29
Operating Cash Flow  -8.36%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -54.66 -114.71 -122.23 -209.4
Cash From Investing Activities -64.36 -210.57 96.63 12.49
Cash From Financing Activities 1.94 15.4 5.86 101.8
Net Change in Cash -117.07 -309.87 -19.74 -95.11
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SRPT Price Commentary

Write your thoughts about Sarepta Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ken Laing
Ken Laing Mar 31, 2021 7:46
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great opportunity to add, its just market rotation that has made it too low
Smooth Operator
Smooth_Operator Mar 01, 2021 14:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
overhyped company that has never delivered on their mandate. Price target 40
Simone Canalicchio
Simone Canalicchio Feb 26, 2021 23:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why this sadness although the vaccine?
Ken Laing
Ken Laing Jan 25, 2021 17:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Back to 170 within 6 months. Over 200 by end of the year.
Anfangell Anfangell
Anfangell Anfangell Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Huge opportunity now to buy this Stock!!...I am in
Ahzam Ali
Ahzam Ali Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How high will it go?
Anfangell Anfangell
Anfangell Anfangell Jan 11, 2021 12:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As you can see now...And just beginning of rebound ;)
Leon Li
Leon Li Jan 08, 2021 18:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why has this stock dropped 50% today??
Shen Jie
Shen Jie Jan 08, 2021 18:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Because people mispret a research report , and solely on just one of their studies .
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email